Dong-A ST Signs Agreement to Support Osteoporosis Treatment for Vulnerable Groups

At the osteoporosis patient medication support agreement ceremony, Kim Min-young, President of Dong-A ST (right), and Noh Hwi-sik, Chairman of Hanmaeum Social Welfare Foundation, are posing for a commemorative photo.

[Asia Economy Reporter Lee Gwan-joo] Dong-A ST announced on the 15th that it has signed a business agreement with Hanmaeum Social Welfare Foundation to support osteoporosis treatment for vulnerable groups.

According to the agreement, Dong-A ST will donate the osteoporosis treatment drug 'Teribone Subcutaneous Injection' to Hanmaeum Social Welfare Foundation, continuing from last year. Hanmaeum Social Welfare Foundation will screen and select the recipients, and the selected individuals will receive up to a one-year supply of Teribone Subcutaneous Injection.

A Dong-A ST official stated, “Osteoporosis refers to a condition where bone mass decreases and strength weakens with age, increasing the risk of fractures. Since there are no obvious symptoms, it is especially dangerous for vulnerable groups and elderly women,” adding, “We hope that the osteoporosis treatment Teribone Subcutaneous Injection will help vulnerable groups and elderly women live happy lives without suffering from fractures.”

Dong-A ST and Dong-A Pharmaceutical, subsidiaries of Dong-A Socio Holdings, have established a Social Value Committee to continue activities for sustainable management and co-growth with society. Dong-A ST is engaged in activities such as supporting medication costs for low-income cancer patients and donating growth hormones for children with short stature. Dong-A Pharmaceutical supports sanitary pads for vulnerable women and low-income youth and continuously introduces eco-friendly products, maintaining efforts to protect the environment.

This content was produced with the assistance of AI translation services.